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Aim Prior evidence observed no predictive utility of coronary CT angiography (CCTA) over the coronary artery calcium
score (CACS) and the Framingham risk score (FRS), among asymptomatic individuals. Whether the prognostic value
of CCTA differs for asymptomatic patients, when stratified by CACS severity, remains unknown.
Methods
and results
From a 12-centre, 6-country observational registry, 3217 asymptomatic individuals without known coronary artery
disease (CAD) underwent CACS and CCTA. Individuals were categorized by CACS as: 0–10, 11–100, 101–400,
401–1000, .1000. For CCTA analysis, the number of obstructive vessels—as defined by the per-patient presence of
a ≥50% luminal stenosis—was used to grade the extent and severity of CAD. The incremental prognostic value of
CCTA over and above FRS was measured by the likelihood ratio (LR) x2, C-statistic, and continuous net reclassification
improvement (NRI) for prediction, discrimination, and reclassification of all-cause mortality and non-fatal myocardial
infarction. During a median follow-up of 24 months (25th–75th percentile, 17–30 months), there were 58 composite
end-points. The incremental value of CCTA over FRS was demonstrated in individuals with CACS .100 (LRx2,
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25.34; increment in C-statistic, 0.24; NRI, 0.62, all P, 0.001), but not among those with CACS ≤100 (all P . 0.05). For
subgroups with CACS.100, the utility of CCTA for predicting the study end-point was evident among individuals whose
CACS ranged from 101 to 400; the observed predictive benefit attenuated with increasing CACS.
Conclusion Coronary CT angiography provides incremental prognostic utility for prediction of mortality and non-fatal myocardial
infarction for asymptomatic individuals with moderately high CACS, but not for lower or higher CACS.
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Introduction
Office-based cardiovascular event prediction algorithms have been
utilized for future risk stratification in asymptomatic populations,
and are useful for identifying individuals who will benefit from
preventive therapies.1 Yet, these clinical prediction methods are
less effective for identifying specific individuals who are at risk for
adverse clinical events.2 –4 Recently, non-invasive imaging modalities
for the identification of subclinical atherosclerosis have emerged as
robust methods that augment identification of individuals at risk, in-
cremental to office-based risk assessments.5 Among these modal-
ities, the coronary artery calcium score (CACS) has been widely
used, and multiple population-based studies demonstrated that
CACS provided powerful prognostic information across different
age categories, gender, and ethnicities.6– 8
Recently, coronary computed tomographic angiography (CCTA)
has emerged as an non-invasive cardiovascular imaging modality
that enables visualization of both calcified and non-calcified athero-
sclerotic plaques, with high diagnostic performance for identification
and exclusion of coronary luminal stenoses.9,10 Prior investigations
haveexamined the utilityof CCTA forassessing future cardiovascular
risk amongasymptomatic individuals.11– 15 Recently, our investigative
group observed no added benefit of CCTA for risk stratification
beyond clinical risk factor scoring and CACS.16 Nevertheless, given
the heterogeneity of this population, it remains to be clarified
whether the prognostic value of CCTA differs according to varying
CACS severity. Consequently, in a large multinational prospective
study, we sought to determine the prognostic value of CCTA accord-
ing to varying CACS categories in a population of asymptomatic
patients.
Methods
Design overview, setting, and participants
The study design and rationale of the CONFIRM (COronary CT Angiog-
raphy EvaluatioN For Clinical Outcomes: An InteRnational Multicenter)
registry has been described elsewhere.17 In brief, the CONFIRM registry
was designed to evaluate the ability of CCTA findings to predict mortality
and major adverse cardiac events. Overall, 27 125 patients who under-
went CCTA at 12 centres in 6 countries (Canada, Germany, Italy,
South Korea, Switzerland, and USA) were initially enrolled between
February 2003 and December 2009. Inclusion criteria were age 18
years or older, availability of CCTA by scanner with 64-detector rows
or greater, and the presence of interpretable CCTA. For the purpose
of this study, at baseline, persons were deemed ineligible for inclusion if
they had previously experienced chest pain (n ¼ 14 063), unknown
symptom status (n ¼ 4685), a prior history of myocardial infarction
(MI), coronary revascularization, and cardiac transplantation (n ¼ 752),
or the absence of concurrent CACS or follow-up data for all-cause
mortality or non-fatal MI (n¼ 4373). Clinical indications for CCTA in indi-
vidualswithoutchestpain in theCONFIRMregistrywere for theassessment
of coronary artery disease (CAD) in individuals with a history of peripheral
arterial disease, cerebrovascular disease, or multiple CAD risk factors,
individuals with pre-operative evaluation or pre-electrophysiological
procedure evaluation (e.g. left atrial appendage evaluation, pulmonary
vein mapping), or individuals with non-major congenital heart disease
including atrial septal defect or ventricular septal defect.
Hence, the analytic sample consisted of 3217 asymptomatic individuals
from seven centres in five countries (Canada, Italy, Germany, South
Korea, and USA) for the current study. Each of the study centres’ institu-
tional review boards approved the study protocol, and all of the partici-
pants provided informed consent.
Data acquisition and image analysis
Multi-detector row CT scanners consisting of 64-rows or greater
acquired CACS and CCTA. Data acquisition and image post-processing,
and data interpretation,wereperformed according to theguideline of the
Society of Cardiovascular Computed Tomography (SCCT).18,19 The
coronary artery calcium score was measured using the scoring system
(in units) described by Agatston et al.20 The mean dose length product
derived from CCTA and coronary artery calcium scan was 726+
316 mGy × cm.
The definition of coronary atherosclerosis by CCTA analysis was any
tissue structures .1 mm2, which were either within the lumen of the
coronary artery or adjacent to the coronary artery lumen that could
be distinguished from neighbouring epicardial fat, pericardial tissue, or
the artery lumen itself. All identified lesions were examined by
maximum-intensity-projection and multi-planar reconstruction techni-
ques along multiple longitudinal axes and in the transverse plane. Identi-
fied plaques were assigned according to a modified 16-segment
American Heart Association coronary tree model:21 left main; proximal,
mid, and distal left anterior descending (LAD) artery; first and second di-
agonal branches of the LAD; proximal and distal left circumflex artery;
first and second obtuse marginal branches of the left circumflex artery;
proximal, mid, and distal right coronary artery; posterior descending
artery; and posterolateral branches (left or right). We defined obstruct-
ive CAD as coronary artery segments exhibiting plaque with a luminal
diameter stenosis ≥50%, and non-obstructive CAD as coronary artery
segments displaying plaque with a luminal diameter stenosis ,50%.
We additionally categorized obstructive CAD as 1-vessel disease (VD),
2-VD, and 3-VD or left main disease.
Patient follow-up
Patients were followed prospectively for 2.5 years. During this study, the
primary outcome measure was a composite of all-cause mortality and
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non-fatal MI. Trained personnel adjudicated all deaths by direct interview
with physicians, next-of-kin, and/or witnesses, by review of hospital
records, or by querying of national medical databases. Non-fatal MI
was defined by the Universal Definition of Myocardial Infarction.22 All
the patients were questioned using a scripted interview, and all proce-
dures were confirmed by review of the patients’ medical record.
Statistical analysis
Continuous variables areexpressedas means+ standarddeviation (SD),
and categorical variables are presented as counts with proportions. Dif-
ferences between continuous variables were analysed by Student’s t-test
and those between categorical variables by the x2 test or Fisher’s exact
test, as appropriate. A 2.5-year horizon period was employed for the
analyses. Cumulative event rates were calculated using the Kaplan–
Meier estimator and compared using the log-rank test.
On the background of CACS, subjects were classified according to the
following categories: 0–10, 11–100, and .100. Furthermore, subjects
with CACS .100 were categorized as 101–400, 401–1000, and
.1000.23 For each CACS category, the incremental prognostic value
of CCTA, above and beyond an office-based risk stratification algorithm,
was evaluated. Specifically, for the office-based risk stratification algo-
rithm, we categorized individuals as low (,10%), low-intermediate
(10–15%), high-intermediate (16–20%), and high (.20%) risk according
to published Framingham 10-year coronary heart disease risk scores.24
Statistical significance for the added prognostic value of each CCTA
category wasevaluated using the likelihood ratio (LR)x2 test,25 the differ-
ence in C-statistic (DC-statistic),26,27 and continuous net reclassification
improvement (cNRI).28,29 A standard bootstrap method was employed
to generate the corresponding confidence intervals (CIs) for estimates.
A two-tailed P-value ,0.05 was considered statistically significant. All
analyses were performed using SAS (version 9.2, SAS Institute, Inc.,
Cary, NC, USA).
Results
Baseline characteristics
During a median follow-up of 24 months (25th–75th percentile:
17–30 months), there were 58 composite end-points among 3217
individuals (1.8% during 2.5 years). Table 1 reports the baseline car-
diovascular risk factors, stratified by CACS categories above and
below 100. Subjects with CACS .100 tended to be older, male,
and had a higher prevalence of hypertension, diabetes, current
smoking, and dyslipidaemia (all P, 0.05). Figure 1 illustrates the
prevalence of CAD as well as extent and severity among patients
with CACS above and below 100. As expected, prevalent any CAD
including both non-obstructive and obstructive was higher in those
with a CACS .100 (87 vs. 43%, P, 0.001). The proportion of indi-
viduals with obstructive CAD was also higher on the background of
CACS .100 (42 vs. 9%, P, 0.001). Likewise, the percentage in the
number of increasing stenosed vessels was higher in patients with a
CACS .100 when compared with those whose CACS was ≤100
(all, P, 0.001).
Clinical outcomes
Over the course of the study period, the overall Kaplan–Meier
2.5-year cumulative event estimate was 2.3% (95% CI, 1.9–2.8%)
(Table 2). Specifically, the Kaplan–Meier 2.5-year cumulative event
estimate was 1.3% among individuals with CACS ≤100, increasing
to 5.1% (95% CI, 3.7–6.9%) among individuals with CACS .100
(log-rank, P, 0.001). Among the subgroups with CACS .100, the
composite event estimates increased proportionally with increasing
CACS categories.
Incremental value of coronary CT
angiography in addition to the
Framingham risk score
In Table 3, adding CCTA to a model including the FRS significantly
improved the prediction of the composite end-point for those with
CACS .100: LRx2 ¼ 25.34, cNRI ¼ 0.62 (95% CI, 0.24–1.02),
and DC-statistic ¼ 0.24 (95% CI, 0.11–0.37), all P, 0.001. Con-
versely, the incremental value of CCTA over and above FRS was non-
significant in patients with CACS≤100: LRx2 ¼ 6.30 and 2.84 among
individuals with a CACS of 0–10, and 11–100, both P. 0.05.
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Table 1 Baseline characteristics of study population according to coronary artery calcium score categories
Variables Total (n 5 3217) CACS P-value
≤100 (n 5 2392) >100 (n5 825)
Age (years) 57+12 55+11 62+11 ,0.001
Gender (male) 2031 (63%) 1430 (60%) 601 (73%) ,0.001
Hypertension 1458 (46%) 994 (42%) 464 (57%) ,0.001
Diabetes 431 (13%) 253 (11%) 178 (22%) ,0.001
Current smoking 432 (13%) 295 (12%) 137 (17%) 0.001
BMI (kg/m2) 27+5 27+5 28+5 0.001
Dyslipidaemia 1715 (54%) 1206 (51%) 509 (62%) ,0.001
Total cholesterol 195+45 197+45 183+42 ,0.001
HDL cholesterol 54+16 54+16 49+15 ,0.001
LDL cholesterol 119+37 121+37 110+35 ,0.001
Continuous values are mean+ SD and categorical values are number and percentage (%).
BMI, indicates body mass index; CACS, coronary artery calcium score; HDL, high-density lipoprotein; LDL, low-density lipoprotein; n, number.
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Continuous NRI and the DC-statistic also demonstrated negligible
added benefit of CCTA over FRS in these subgroups.
Among patients with CACS .100, the incremental benefit of
CCTA over FRS was particularly evident for those with a CACS
between 101 and 400. The LRx2 was 14.68 (P ¼ 0.005) and
the ability of CCTA to correctly reclassify and discriminate indi-
viduals from FRS was significant: cNRI ¼ 0.74 (95% CI, 0.23–1.38,
P ¼ 0.008) and DC-statistic ¼ 0.13 (95% CI, 0.03–0.23, P ¼ 0.011).
However, the incremental value of CCTA for predicting the com-
posite end-point was attenuated among patients when CACS
increased .400 (Table 3). The LRx2 gradually declined becoming
marginally non-significant for individuals with a CACS between 401
and 1000 (9.22, P ¼ 0.06), and in those with CACS .1000 (5.36,
P ¼ 0.25). Likewise, cNRI was mitigated in patients whose CACS
was .1000 (0.57, 95% CI, 20.23–1.18, P ¼ 0.16), albeit with
improved discrimination (DC-statistic ¼ 0.23, P ¼ 0.01).
Discussion
In this global multicentre study, we set out to determine whether
CCTA improved risk prediction for future fatal and non-fatal events
over FRS when stratified by CACS severity, in an asymptomatic
Figure1 Prevalence of coronary artery disease evaluated by coronary computed tomographic angiography according to coronary artery calcium
score categories. Number and percentage (%). Any CAD indicates obstructive and non-obstructive coronary artery disease; CACS, coronaryartery
calcium score; CCTA, coronary CT angiography; LM, left main disease; VD, vessel disease.
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Table 2 Composite outcomes of all-cause mortality and non-fatal myocardial infarction according to coronary artery
calcium score categories during 2.5-year follow-up period
Number of subjects Number of composite
outcomes (number of MIs)
Kaplan–Meier 2.5-year cumulative
event estimates (95% CI)
Total 3217 58 (12) 2.3% (1.9–2.8)
0≤ CACS ≤10 1818 19 (2) 1.3% (0.9–2.0)
10, CACS ≤100 574 6 (1) 1.3% (0.6–2.7)
CACS .100 825 33 (9) 5.1% (3.7–6.9)
100, CACS ≤400 472 14 (4) 3.6% (2.1–5.8)
400, CACS ≤1000 217 12 (2) 6.8% (4.0–11.2)
CACS .1000 136 7 (3) 7.8% (4.1–14.0)
CACS, indicates coronary artery calcium score; CI, confidence interval; No, number; MIs, non-fatal myocardial infarctions.
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Table 3 Incremental prognostic benefit of coronary computed tomographic angiography over Framingham risk scoring in predicting 2.5-Year Risk of composite
outcome of all-cause mortality and non-fatal myocardial infarction according to coronary artery calcium score categories
CACS categories 0–10 11–100 >100 Subgroup of CACS >100
101–400 401–1000 >1000
Number of subjects (number of events) 1818 (19) 574 (6) 825 (33) 472 (14) 217 (12) 136 (7)
Likelihood ratio tests
Likelihood ratio x2 6.30 2.84 25.34 14.68 9.22 5.36
P-value 0.178 0.584 ,0.001 0.005 0.056 0.252
cNRIs
Proportion of event correctly reclassified 20.16 0.31 0.07 0.05 0.70 0.59
Proportion of non-event correctly reclassified 0.56 20.23 0.55 0.70 0.04 20.02
cNRI (95% CI) 0.39 (20.04–0.94) 0.08 (21.24–0.77) 0.62 (0.24–1.02) 0.74 (0.23–1.38) 0.74 (0.12–1.17) 0.57 (20.23–1.18)
P-value 0.092 0.300 ,0.001 0.008 0.010 0.160
C-statistics
C of FRS (95% CI) 0.64 (0.53–0.75) 0.68 (0.40–0.97) 0.53 (0.42–0.64) 0.64 (0.49–0.78) 0.58 (0.39–0.77) 0.56 (0.34–0.78
C of FRS + CCTA (95% CI) 0.71 (0.59–0.83) 0.73 (0.50–0.96) 0.77 (0.69–0.85) 0.77 (0.61–0.92) 0.75 (0.63–0.87) 0.78 (0.67–0.90)
DC (95% CI) 0.07(20.02–0.17) 0.05 (20.05–0.14) 0.24 (0.11–0.37) 0.13 (0.03–0.23) 0.17 (20.03–0.37) 0.23 (0.05–0.40)
P-value 0.145 0.312 ,0.001 0.011 0.088 0.013
C, indicates C-statistics; CACS, coronary artery calcium score; CCTA, coronary computed tomographic angiography; DC, difference in C-statistic; FRS, Framingham Risk Score; cNRI, continuous net reclassification improvement; CI, confidence
interval.
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population. The major finding was that CCTA improved risk predic-
tion for future fatal and non-fatal events by adding further prognostic
information to the FRS in patients whose CACS was .100.
The addedprognostic value ofCCTAover theFRS was particularly
proven in subjects with a CACS between 101 and 400. Most reclas-
sification of this subgroup occurred in the non-event proportion
(0.70 of 0.74), suggesting most individuals were correctly reclassified
to a lower-risk category by CCTA. The incremental benefit of CCTA
over FRS may, in large, be attributable to the diagnostic accuracy
within this CACS category.30 In addition, individuals with a CACS
between 101 and 400 were accompanied by intermediate event
risk (3.6%), allowing CCTA to discriminate future risk. Therefore,
CCTA may be considered for reclassification especially in this subset
of individuals. Forthcoming studies are needed to test this notion.
Although the added benefit of CCTA over FRS was statistically sig-
nificant in patients with CACS.100, it was limited among individuals
whose CAC exceeded 400. Modest improvements in reclassification
occurred in individuals with CACS between 401 and 1000, and dis-
crimination for individuals with CACS .1000. Notably, the lack of
a beneficial impact of CCTA among individuals with a very high
calcium score may likely be afforded to a decreased diagnostic accur-
acy of CCTA due to beam hardening and blooming artefacts.31 In a
meta-analysis, Abdulla et al.30 documented that the overall diagnostic
accuracy of CCTA was markedly reduced in patients with CACS
.400. In one other study,32 the diagnostic precision of CCTA for
detecting obstructive CAD diminished in patients with severe calci-
fication (i.e. CACS .600). Consequently, other functional tests,
for instance, myocardial perfusion imaging or exercise stress testing,
may need to be considered instead of CCTA in this population.
Likewise, the incremental benefit of CCTA over and above FRS
was negligible in patients with CACS ≤100. Most (74%) of the
study population consisted of patients with a CACS ≤100, which is
fitting with past large-scale epidemiological studies.6,33 This finding
may be explained by the inability of CCTA to reclassify individuals
to a lower-risk category in this population with low event rates.
Indeed, the Kaplan–Meier 2.5-year event estimate for individuals
with CACS ≤100 was only 1.3% and which was significantly lower
than those with CACS .100. Large-scale epidemiological studies
have also reported a very low risk for persons in this category.6,33,34
Even in a symptomatic population, patients with CACS ≤100 have a
very low probability (,2%) of myocardial ischaemia on the nuclear
stress test.35,36 Based on Bayes theorem, it may be challenging for
CCTA to provide any further incremental value in this very-low-risk
population compared with, for example, intermediate risk patients
with CACS 101–400.37 Therefore, it is questionable whether
CCTA should also be performed in populations whose CACS
≤100 for further risk stratification. Rather, lifestyle modification
and non-pharmacological interventions should be recommended
for this population. Reassessment of coronary plaque burden using
only CACS could further be considered in 3–5 years.38,39
Nevertheless, the current study observations may have important
clinical ramifications. Early studies with CCTA employed non-
negligible doses of radiation that were similar, or even higher, than
current generation nuclear stress testing; doses that contrasted un-
favourably to the low-dose CACS.40 However, recent technological
advances in CCTA now enable performance of CCTA at doses even
lower than CACS, and can now often be performed in ranges
,1 mSv.41,42 Furthermore, CCTA can directly and accurately iden-
tify location and severity of coronary plaque, while a relationship
between CACS and severity of luminal stenosis is weak, especially
in patients with acute coronary syndrome.43,44 Recent publications
also showed clinical importance of vulnerable plaque features includ-
ing non-calcified plaque, which was identified by CCTA.45,46 There-
fore, future studies evaluating plaque characteristics by CCTA
using very low radiation dose image acquisition techniques may iden-
tify improved prognostic utility beyond CACS and FRS in asymptom-
atic populations.
This study had some limitations that bear mentioning. Given the
observational nature of the study, the potential biases—including
population heterogeneity, inter-observervariability in CCTAdiagno-
sis, as well as other unobserved confounders, cannot be dismissed.
To minimize selection bias, we prospectively employed standardized
data definitions and only included experienced CCTA centres
whereby persons with expert proficiency led acquisition and inter-
pretation of all CCTAs in the current registry.17 While this cohort
is the largest global multicentre CCTA study to date, lack of added
prognostic value in patients with CACS,100 and.400 may be sec-
ondary to a reduced study sample size and limited follow-up duration
in these subgroups. Also, considering FRS reflects 10-year risk esti-
mate, a 2.5-year follow-up duration of the current study limits long-
term prognostic utility of CCTA when added to FRS predictors.
Future studies will be needed to fully address these questions, and
further follow-up this study cohort along with an expansion of the
current registry size is already underway.
Conclusions
For asymptomatic individuals with moderately elevated CACS,
CCTA improves prediction, discrimination and reclassification for
risk of future fatal and non-fatal events above and beyond clinical
risk assessment. Coronary CT angiography does not reliably
improve risk stratification for individuals with lower or higher CACS.
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